Physician profile
Gigi E Baker
NPI 1184666117
$4,786.71
in general payments reported to CMS, 2019-2025
32 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,922 · 2020: $697 · 2021: $727 · 2022: $136 · 2023: $228 · 2024: $305 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $493.44 | 2019-2025 | |
| Lilly USA, LLC | $434.39 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $431.53 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $395.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Allergan, INC. | $344.36 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.10 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.64 | 2019-2021 | |
| Amgen INC. | $308.81 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $226.02 | 2024-2025 | Freestyle Libre |
| Dexcom, INC. | $218.13 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $174.67 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $140.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $95.87 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $94.04 | 2019-2021 | |
| Radius Health, INC. | $87.71 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81.48 | 2019-2021 | |
| Abbvie INC. | $81.20 | 2019-2023 | Qulipta |
| Merck Sharp & Dohme LLC | $79.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $70.60 | 2021 | |
| Amarin Pharma, INC. | $70.49 | 2019-2020 | |
| Glaxosmithkline, LLC. | $59.12 | 2021-2023 | Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.17 | 2019-2020 | |
| Genzyme Corporation | $44.42 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $39.11 | 2020-2021 | |
| Inspire Medical Systems, INC. | $24.14 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $22.92 | 2024 | Gemtesa |
| Edwards Lifesciences Corporation | $19.43 | 2021 | |
| Eisai INC. | $18.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.93 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $15.07 | 2020 | |
| Therapeuticsmd, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gigi Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.